Welcome to the VC Roundup, where we’ll parse through venture capital news related to Philadelphia-based private equity firms and the companies they fund. Subscribe to the roundup as an email newsletter. If you have any VC-related news to pass along to us, please drop us a line.
DEFINITE READS
Reuters has a profile (complete with video) on First Round Capital’s Phineas “Phin” Barnes. Barnes played basketball in college and started his career at AND1, the basketball shoe company that was formally based in Paoli. Since then he has worked at MTV before becoming a principal at First Round.
Safeguard partner company NuPath, the Conshohocken-based specialty pharmaceutical company, has dialed back expectations for its IPO, exactly as Joe Destefeno predicted.
MIGHT BE WORTH YOUR TIME
Jumpstart NJ has invested $500,000 in ConnectYard, a social media platform for educators.
Startup Lucky has a video interview with First Round Capital’s Charlie O’Donnell about receiving funding from customers, effectively putting himself out of a job.
GIVE A GLANCE
Marc Kramer reviews what he learned at a recent venture capital event at the Cira Center last week. Kramer says that companies are being launched for less money, and VC’s need to adjust accordingly.
Radnor-based Cross Atlantic Capital Partners has invested $6.3 million in a Series D round for Interactions, a Massachusetts-based software company. XACP has been busy, investing $4 million in Heath Market Science last week.
The VC Roundup will deliver Philadelphia private equity news hot and fresh every Tuesday morning.
Join our growing Slack community
Join 5,000 tech professionals and entrepreneurs in our community Slack today!
Donate to the Journalism Fund
Your support powers our independent journalism. Unlike most business-media outlets, we don’t have a paywall. Instead, we count on your personal and organizational contributions.

Half of Pennsylvania’s federal buildings are set to be sold under Trump admin plan

RealLIST Startups 2025: Meet 20 Philly startups hot on the track to success

Biotech startups are still winning federal grants, accelerator founder says — but the money is taking longer to trickle in
